Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1

Gupta, K.M.; Pearce, S.M.; Poursaid, A.E.; Aliyar, H.A.; Tresco, P.A.; Mitchnik, M.A.; Kiser, P.F.

Journal of Pharmaceutical Sciences 97(10): 4228-4239

2008

ISSN/ISBN: 1520-6017
PMID: 18338805
DOI: 10.1002/jps.21331
Document Number: 203800
Women-controlled methods for prevention of male-to-female sexual transmission of HIV-1 are urgently needed. Providing inhibitory concentrations of HIV-1 reverse transcriptase inhibitors to impede the replication of the virus in the female genital tissue offers a mechanism for prophylaxis of HIV-1. To this end, an intravaginal ring device that can provide long duration delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1, was developed utilizing a medical-grade polyether urethane. Monolithic intravaginal rings were fabricated and sustained release with cumulative flux linear with time was demonstrated under sink conditions for a period of 30 days. The release rate was directly proportional to the amount of drug loaded. Another release study conducted for a week utilizing liposome dispersions as sink conditions, to mimic the partitioning of dapivirine into vaginal tissue, also demonstrated release rates constant with time. These results qualify polyether urethanes for development of intravaginal rings for sustained delivery of microbicidal agents.

Document emailed within 0-6 h
Secure & encrypted payments

Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1

Puthanakit, T.; Jourdain, G.; Hongsiriwon, S.; Suntarattiwong, P.; Chokephaibulkit, K.; Sirisanthana, V.; Kosalaraksa, P.; Petdachai, W.; Hansudewechakul, R.; Siangphoe, U.; Suwanlerk, T.; Ananworanich, J.; Bunupuradah, T.; Phasomsap, C.; Kaew-on, P.; Kanjanavanit, S.; Hinjiranandana, T.; Layangool, P.; Kamonpakorn, N.; Buranabanjasatean, S.; Ngampiyaskul, C.; Chotpitayasunondh, T.; Chanpradub, S.; Leawsrisuk, P.; Chearskul, S.; Vanprapar, N.; Phongsamart, W.; Lapphra, K.; Chearskul, P.; Wittawatmongkol, O.; Prasitsuebsai, W.; Intalapaporn, K.; Kongstan, N.; Pannin, N.; Maleesatharn, A.; Khumcha, B.; Aurpibul, L.; Wongnum, N.; Nadsasarn, R.; Lumbiganon, P.; Tharnprisan, P.; Udompanich, T.; Yentang, M.; Khonponoi, A.; Maneerat, N.; Denjunta, 2010: HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy HIV Medicine 11(9): 565-572
Lee, B.; Aurpibul, L.; Sirisanthana, V.; Mangklabruks, A.; Sirisanthana, T.; Puthanakit, T. 2009: Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand HIV Medicine 10(2): 72-78
Antinori, A.; Zaccarelli, M.; Cingolani, A.; Forbici, F.; Rizzo, M.G.; Trotta, M.P.; Di Giambenedetto, S.; Narciso, P.; Ammassari, A.; Girardi, E.; De Luca, A.; Perno, C.F. 2002: Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure Aids Research and Human Retroviruses 18(12): 835-838
Van Herrewege, Y.; Michiels, J.; Van Roey, J.; Fransen, K.; Kestens, L.; Balzarini, J.; Lewi, P.; Vanham, G.; Janssen, P. 2004: In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides Antimicrobial Agents and ChemoTherapy 48(1): 337-339
Lalezari, J.P.; DeJesus, E.; Northfelt, D.W.; Richmond, G.; Wolfe, P.; Haubrich, R.; Henry, D.; Powderly, W.; Becker, S.; Thompson, M.; Valentine, F.; Wright, D.; Carlson, M.; Riddler, S.; Haas, F.F.; DeMasi, R.; Sista, P.R.; Salgo, M.; Delehanty, J. 2003: A controlled Phase Ii trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults Antiviral Therapy 8(4): 279-287
Clark, J.T.; Clark, M.R.; Shelke, N.B.; Johnson, T.J.; Smith, E.M.; Andreasen, A.K.; Nebeker, J.S.; Fabian, J.; Friend, D.R.; Kiser, P.F. 2014: Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy Plos one 9(3): E88509
Nel, A.; Haazen, W.; Nuttall, J.; Romano, J.; Rosenberg, Z.; van Niekerk, N.ët. 2014: A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women Aids 28(10): 1479-1487
Johnson, T.J.; Srinivasan, P.; Albright, T.H.; Watson-Buckheit, K.; Rabe, L.; Martin, A.; Pau, C.-P.; Hendry, R.M.; Otten, R.; McNicholl, J.; Buckheit, R.; Smith, J.; Kiser, P.F. 2012: Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings Antimicrobial Agents and ChemoTherapy 56(3): 1291-1299
Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720
Ripamonti, D.; Maggiolo, F. 2008: Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection Current Opinion in Investigational Drugs 9(8): 899-912
Dieterich, D.T. 2003: Long-term complications of nucleoside reverse transcriptase inhibitor therapy Aids Reader 13(4): 176-184; 187
Peng, Z-Gen.; Chen, H-Shan.; Wang, L.; Liu, G. 2008: Anti-HIV activities of HIV-1 reverse transcriptase inhibitor racemic 11-demethyl-calanolide A Yao Xue Xue Bao 43(5): 456-460
Chen, C.Y.; Tan, L. 1999: Chemical process evolution of efavirenz, a potent non-nucleosidal HIV reverse transcriptase inhibitor Enantiomer 4(6): 599-608
McMahon, J.B.; Buckheit, R.W.; Gulakowski, R.J.; Currens, M.J.; Vistica, D.T.; Shoemaker, R.H.; Stinson, S.F.; Russell, J.D.; Bader, J.P.; Narayanan, V.L.; Schultz, R.J.; Brouwer, W.G.; Felauer, E.E.; Boyd, M.R. 1996: Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor Journal of Pharmacology and Experimental Therapeutics 276(1): 298-305
Mesquita, P.M.M.; Rastogi, R.; Segarra, T.J.; Teller, R.S.; Torres, N.Merna.; Huber, A.M.; Kiser, P.F.; Herold, B.C. 2012: Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection Journal of Antimicrobial ChemoTherapy 67(7): 1730-1738
Weidle, P.J.; Moore, D.; Mermin, J.; Buchacz, K.; Were, W.; Downing, R.; Kigozi, A.; Ndazima, V.; Peters, P.; Brooks, J.T. 2008: Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda Aids Patient Care and Stds 22(10): 787-795
Aurpibul, L.; Puthanakit, T.; Taecharoenkul, S.; Sirisanthana, T.; Sirisanthana, V. 2009: Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy Aids Patient Care and Stds 23(12): 1067-1071
Germanaud, D.; Derache, A.; Traore, M.; Madec, Y.; Toure, S.; Dicko, F.; Coulibaly, H.; Traore, M.; Sylla, M.; Calvez, V.; Marcelin, A.-G. 2010: Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali Journal of Antimicrobial ChemoTherapy 65(1): 118-124
Voorman, R.L.; Maio, S.M.; Hauer, M.J.; Sanders, P.E.; Payne, N.A.; Ackland, M.J. 1998: Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(7): 631-639
Mankhatitham, W.; Lueangniyomkul, A.; Manosuthi, W. 2011: Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen Southeast Asian Journal of Tropical Medicine and Public Health 42(3): 651-658